Modulators of plasminogen activator inhibitor-1 (PAI-1) activity

Drugs of the Future

Volumn 22, Issue 1, 1997, Pages 45-52

  Charlton, Peter ^a  

^a Cantab Pharmaceuticals Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CLB 2C8; MONOCLONAL ANTIBODY MAI 12; PIPERAZINE DERIVATIVE; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; UNCLASSIFIED DRUG; XR 334; XR 5082; XR 5118;

CANCER; ENDOTHELIUM CELL; FIBRINOLYSIS; GENE EXPRESSION REGULATION; HEART INFARCTION; HUMAN; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; THROMBOSIS; VASCULAR SMOOTH MUSCLE;

EID: 0030965527     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (113)

1. CDER Trust. Prevention of venous thromboembolism. European Consensus Statement, Windsor, UK, 1-5 November 1991. Med-Orion: London 1992.
2. Declerck, P.J., Juhan-Vague, I., Felez, J., Wiman, B. Minisymposium: The role of the fibrinolytic system in the pathophysiology and treatment of thrombosis. J Intern Med 1994, 236: 425-32.
3. Krishnamurti, C., Alving, B.M. Plasminogen activator inhibitor type 1: biochemistry and evidence for modulation of fibrinolysis in vivo. Semin Thromb Hemost 1992, 18: 67-80.
4. Edelberg, J.M., Sane, D.C., Pizzo S.V. Vascular regulation of plasminogen activator inhibitor-1 activity. Semin Thromb Hemost 1994, 20: 319-23.
5. Kooistra, T., Lansink, M., Emeis, J. Stimulators of tissue-type plasminogen activator. Drugs Fut 1996, 21: 291-9.
6. Potempa, J., Korzus, E., Travis, J. The serpin superfamily of proteinase inhibitors: Structure, function and regulation. J Biol Chem 1994, 269: 15957-60.
7. Tucker, H.M., Gerard, R.D. Sequence requirements in the reactive-center loop of plasminogen-activator inhibitor-1 for recognition of plasminogen activators. Eur J Biochem 1996, 237: 180-7.
8. Ny, T., Sawdey, M., Lawrence, D., Millan, J.L., Loskutoff, D.J. Cloning and sequence of a cDNA coding for the human β-migrating endothelial cell type plasminogen activator inhibitor. Proc Natl Acad Sci USA 1986, 83: 6776-80.
9. Sancho, E., Declerck, P.J., Price, N.C., Kelly, S.M., Booth, N.A. Conformational studies on plasminogen activator inhibitor (PAI-1) in active, latent, substrate and cleaved forms. Biochemistry 1995, 34: 1064-9.
10. Lindahl, T.L., Ohlsson, P.I., Wiman, B. The mechanism of the reaction between human plasminogen-activator inhibitor 1 and tissue plasminogen activator. Biochem J 1990, 265: 109-13.
11. Sancho, E., Tonge, D.W., Hockney, R.C., Booth, N.A. Purification and characterization of active and stable recombinant plasminogen activator inhibitor accumulated at high levels in Escherichia coli. Eur J Biochem 1994, 224: 125-34.
12. Mottonen, J., Strand, A., Symersky, J. et al. Structural basis of latency in plasminogen activator inhibitor-1. Nature 1992, 355: 270-3.
13. Aertgeerts, K., De Bondt, H.L., De Ranter, C., Declerck, P.J. Crystallization and X-ray diffraction data of the cleaved form of plasminogen activator inhibitor-1. Proteins Struct Funct Genet 1995, 23: 118-21.
14. Aertgeerts, K., De Bondt, H.L., De Ranter, C.J., Declerck, P.J. Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1. Nat Struct Biol 1995, 2: 891-7.
15. Dawson, S., Henney, A. The status of PAI-1 as a risk factor for arterial and thrombotic disease: A review. Atherosclerosis 1992, 95: 105-17.
16. Björquist, P., Brohlin, M., Ehnebom, J. et al. Plasminogen activator inhibitor type-1 interacts exclusively with the proteinase domain of tissue plasminogen activator. Biochim Biophys Acta 1994, 1209: 191-202.
17. Torr-Brown, S.R., Sobel, B.E. Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets. Thromb Res 1993, 72: 413-21.
18. Booth, N.A., Simpson, A.J., Croll, A., Bennett, B., MacGregor, I.R. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol 1988, 70: 327-33.
19. Booth, N.A., Croll, A., Bennett, B. The activity of plasminogen activator inhibitor-1 (PAI-1) of human platelet. Fibrinolysis 1990, 4 (Suppl. 2): 138-40.
20. Stringer, H.A.R., van Swieten, P., Heijnen, H.F.G., Sixma, J.J., Pannekoek, H. Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Studies with thrombi generated in the Chandler loop. Arterioscler Thromb 1994, 14: 1452-8.
21. van Meijer, M., Pannekoek, H. Structure of plasminogen activator inhibitor-1 (PAI-1) and its function in fibrinolysis: An update. Fibrinolysis 1995, 9: 263-76.
22. van Meijer, M., Klein Gebbink, R., Preissner, K.T., Pannekoek, H. Determination of the vitronectin binding site on plasminogen activator inhibitor-1 (PAI-1). FEBS Lett 1994, 352: 342-6.
23. Lawrence, D.A., Berkenpas, M.B., Palaniappan, S., Ginsburg, D. Localization of vitronectin binding domain in plasminogen activator inhibitor-1. J Biol Chem 1994, 21: 15223-8.
24. Reilly, T.M., Mousa, S.A., Seetharam, R., Racanelli, A.I. Recombinant plasminogen activator inhibitor type 1: A review of structural, functional and biological aspects. Blood Coagul Fibrinolysis 1994, 5: 73-81.
25. Patrassi, G.M., Sartori, M.T., Saggiorato, G., Boeri, G., Girolami, A. Familial thrombophilia associated with high levels of plasminogen activator inhibitor. Fibrinolysis 1992, 6: 99-103.
26. Grimaudo, V., Bachmann, F., Hauert, J., Christe, M.A., Kruithof, E.K. Hypofibrinolysis in patients with a history of idiopathic deep vein thrombosis and or pulmonary embolism. Thromb Haemost 1992, 67: 397-401
27. Diéval, J., Nguyen, G., Gross, S., Delobel, J., Kruithof, E.K.O. A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1. Blood 1991, 77: 528-32.
28. Lee, M.H., Vosburgh, E., Anderson, K., McDonagh, J. Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding. Blood 1993, 81: 2357-62.
29. Fay, W.P., Shapiro, A.D., Shih, J.L., Schleef, R.R., Ginsburg, D. Complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. New Engl J Med 1992, 327: 1729-33.
30. Schleef, R.R., Higgins, D.L., Pillemer, E., Levitt, L.J. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest 1989, 83: 1747-52.
31. Bick, R.L., Pegram, M. Syndromes of hypercoagulability and thrombosis: A review. Semin Thromb Hemost 1994, 20: 109-32.
32. Knabb, R.M., Chiu, A.T., Reilly, T.M. Effects of recombinant plasminogen activator inhibitor type 1 on fibrinolysis in vitro and in vivo. Thromb Res 1990, 59: 309-17.
33. Potter van Loon, B.J., Rijken, D.C., Brommer, E.J.P., van der Maas, A.P.C. The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility. Thromb Haemost 1992, 67: 101-5.
34. Lang, I.M., Marsh, J.J., Olman, M.A., Moser, K.M., Loskutoff, D.J., Schleef, R.R. Expression of type 1 plasminogen activator inhibitor in chronic pulmonary thromboemboli. Circulation 1994, 89: 2715-21.
35. Åstedt, B., Casslén, B., Lecander, I., Nilsson, L., Norgren, L. Rebound increase of PAI-1 following local intra-arterial rt-PA infusion, a possible cause of reocclusion. Blood Coagul Fibrinolysis 1993, 4: 563-7.
36. Vaughan, D.E., Declerck, P.J., Van Houtte, E., De Mol, M., Collen, D. Reactivated recombinant plasminogen activator inhibitor-1 (PAI-1) effectively prevents thrombolysis in vivo. Thromb Haemost 1992, 68: 60-3.
37. Erikson, L.A., Fici, G.J., Lund, J.E., Boyle, T.P., Routes, H.G., Marotti, K.R. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature 1990, 346: 74-6.
38. Carmeliet, P., Stassen, J.M., Schoonjans, L. et al. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis and thrombolysis. J Clin Invest 1993, 92: 2756-60.
39. Eriksson, P., Kallin, B., van't Hooft, F.M., Bavenholm, P., Hamsten, A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995, 92: 1851-5.
40. Aznar, J., Estellés, A. Role of plasminogen activator inhibitor type 1 in the pathogenesis of coronary artery diseases. Haemostasis 1994, 24: 243-51.
41. Gray, R.P., Mohamed-Ali, V., Patterson, D.L.H., Yudkin, J.S. Determinants of plasminogen activator inhibitor-1 activity in survivors of myocardial infarction. Thromb Haemost 1995, 73: 261-7.
42. Colucci, M., Paramo, J.A., Collen, D. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 1985, 75: 818-24.
43. Wieczorek, I., Ludlam, C.A., Fox, K.A.A. Tissue-type plasminogen activator and plasminogen activator inhibitor activities as predictors of adverse events in unstable angina. Am J Cardiol 1994, 74: 424-9.
44. Gray, R.P., Yudkin, J.S., Patterson, D.L. Plasminogen activator inhibitor: A risk factor for myocardial infarction in diabetic patients. Br Heart J 1993, 69: 228-32.
45. Hamsten, A., de Faire, U., Walldius, G. et al. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987, 2: 3-9.
46. Shimomura, I., Funahashi, T., Takahashi, M. et al. Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity. Nat Med 1996, 2: 800-3.
47. Hamsten, A., Eriksson, P. Fibrinolysis and atherosclerosis: An update. Fibrinolysis 1994, 8: 253-62.
48. Juhan-Vague, I., Alessi, M.C. Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemost 1993, 70: 138-43.
49. Woolf, N., Davies, M.J. Interrelationship between atherosclerosis and thrombosis. In: Thrombosis in Cardiovascular Disorders. V. Fuster, M. Verstraete (Eds.). W.B. Saunders: Philadelphia 1992, 41-77.
50. Lip, G.Y.H., Jones, A.F. Lipoprotein and vascular disease: Thrombogenesis and atherogenesis. Q J Med 1995, 88: 529-39.
51. Desmarais, R.L., Sarembock, I.J., Ayers, C.R., Vernon, S.M., Powers, E.R., Gimple, L.W. Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation 1995, 91: 1403-9.
52. Nordt, T.K., Sawa, H., Fujii, S., Sobel, B.E. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation 1995, 91: 764-70.
53. Raghunath, P.N., Tomaszewski, J.E., Brady, S.T., Caron, R.J., Okada, S.S., Barnathan, E.S. Plasminogen activator system in human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1995, 15: 1432-43.
54. Chomiki, N., Henry, M., Alessi, M.C., Anfosso, F., Juhan-Vague, I. Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls. Thromb Haemost 1994, 72: 44-53.
55. Schneiderman, J., Sawdey, M.S., Keeton, M.R. et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992, 89: 6998-7002.
56. Padró, T., Emeis, J.J., Steins, M., Schmid, K.W., Kienast, J. Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease. Arterioscler Thromb Vasc Biol 1995, 15: 893-902.
57. Lupu, F., Bergonzelli, G.E., Heim, D.A. et al. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 1993, 13: 1090-100.
58. Sawa, H., Lundgren, C., Sobel, B.E., Fujii, S. Increased intramural expression of plasminogen activator inhibitor type 1 after balloon injury: A potential progenitor of restenosis. J Am Coll Cardiol 1994, 24: 1742-8,
59. Fujii, S., Sawa, H., Sobel, B.E. Inhibition of endothelial cell expression of plasminogen activator inhibitor type-1 by gemfibrozil. Thromb Haemost 1993, 70: 642-7.
60. Brown, S.L., Sobel, B.E., Fujii, S. Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. A potential link between lipid lowering and fibrinolysis. Circulation 1995, 92: 767-72.
61. Okada, H., Lundgren, C., Brown, S.L., Vinogradsky, B., Wulfroth, P., Fujii, S. Effect of etofibrate and nicanartine on plasminogen activator inhibitor type-1 production in vitro by cultured vascular cells and on plasma plasminogen activator inhibitor type-1 in vivo in rabbits. Curr Ther Res 1996, 57: 192-202.
62. Wada, H., Mori, Y., Kaneko, T. et al. Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia. Am J Hematol 1993, 44: 112-6.
63. de Bono, D. Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease. Br Heart J 1994, 71: 504-7.
64. Kruithof, E.K.O., Calandra, T., Pralong, G. et al. Evolution of plasminogen activator inhibitor type-1 in patients with septic shock - Correlation with cytokine concentrations. Fibrinolysis 1993, 7: 117-21.
65. Yamashita, M., Darlington, D.N., Weeks, E.J., Jones, R.O., Gann, D.S. Plasminogen activator inhibitor-1 rises after hemorrhage in rats. Am J Physiol 1995, 31: E1065-9.
66. Emeis, J.J., Hoekzema, R., de Vos, A.F. Inhibiting interleukin-1 and tumour necrosis factor-α does not reduce induction of plasminogen activator inhibitor type-1 by endotoxin in rats in vivo. Blood 1995, 85: 115-20.
67. Eitzman, D.T., McCoy, R.D., Zheng, X. et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996, 97: 232-7.
68. Wang, Y., Pratt, J.R., Tam, F.W.K. et al. Up-regulation of type 1 plasminogen activator inhibitor messenger RNA with thrombotic changes in renal grafts. Transplantation 1996, 61: 684-9.
69. Peng, X-R., Hsueh, A.J.W., Ny, T. Transient and cell-specific expression of tissue-type plasminogen activator and plasminogen-activator-inhibitor type 1 results in controlled and directed proteolysis during gonadotropin-induced ovulation. Eur J Biochem 1993, 214: 147-56.
70. Rømer, J., Bugge, T.H., Pyke, C. et al. Impaired wound healing in mice with a disrupted plasminogen gene. Nat Med 1996, 2: 287-92.
71. Pappot, H., Gårdsvoll, H., Rømer, J. et al. Plasminogen activator inhibitor type 1 in cancer: Therapeutic and prognostic implications. Biol Chem Hoppe-Seyler 1995, 376: 259-67.
72. Andreasen, P.A., Georg, B., Lund, L.R., Riccio, A., Stacey, S.N. Plasminogen activator inhibitors: Hormonally regulated serpins. Mol Cell Endocrinol 1990, 68: 1-19.
73. Bacharach, E., Itin, A., Keshet, E. In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis. Proc Natl Acad Sci USA 1992, 89: 10686-90.
74. Foekens, J.A., Schmitt, M., van Putten, W.L.J. et al. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 1992, 52: 6101-95.
75. Grøndahl-Hansen, J., Christensen, I.J., Rosenquist, C. et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993, 53: 2513-21.
76. Danø, K., Behrendt, N., Brünner, N., Ellis, V., Ploug, M., Pyke, C. The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 1994, 8 (Suppl. 1): 189-203.
77. Pedersen, H., Grøndahl-Hansen, J., Francis, D. et al. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res 1994, 54: 120-3.
78. Jänicke, F., Schmitt, M., Graeff, H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost 1991, 17: 303-12.
79. Foekens, J.A., Schmitt, M., van Putten, W.L.J. et al. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 1994, 12: 1648-58.
80. Pyke, C., Kristensen, P., Ralfkiaer, E., Eriksen, J., Danø, K. The plasminogen activation system in human colon cancer: Messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res 1991, 51: 4067-71.
81. Sier, C.F.M., Vloedgraven, H.J.M., Ganesh, S. et al. Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. Gastroenterology 1994, 107: 1449-56.
82. Nekarda, H., Schmitt, M., Ulm, K. et al. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 1994, 54: 2900-7.
83. Kuhn, W., Pache, L., Schmalfeldt, B. et al. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO111) after radical surgery and platinum-based chemotherapy. Gynecol-Oncol 1994, 55: 401-9.
84. Kono, S., Sci, D.M., Rao, J.S., Bruner, J.M., Sawaya, R. Immunohistochemical localisation of plasminogen activator inhibitor type 1 in human brain tumors. J Neuropathol Exp Neurol 1994, 53: 256-62.
85. Buo, L., Meling, G.I., Karlsrud, T.S., Johansen, H.T., Aasen, A.O. Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness. Hum Pathol 1995, 26: 1133-8.
86. Naitoh, H., Eguchi, Y., Ueyama, H., Kodama, M., Hattori, T. Localization of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, 2 and plasminogen in colon cancer. Jpn J Cancer 1995, 86: 48-56.
87. Reilly, D., Christensen, L., Duch, M., Nolan, N., Duffy, M.J., Andreasen, P.A. Type-1 plasminogen activator inhibitor in human breast carcinomas. Int J Cancer 1992, 50: 208-14.
88. Quax, P.H.A., van Muijen, G.N.P., Weening-Verhoeff, E.J.D. et al. Metastatic behaviour of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor and urokinase-mediated matrix degradation. J Cell Biol 1991, 115: 191-9.
89. Kobayashi, H., Fujishiro, S., Terao, T. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res 1994, 54: 6539-48.
90. Schmalfeldt, B., Kuhn, W., Reuning, U. et al. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor and inhibitors types 1 and 2. Cancer Res 1995, 55: 3958-63.
91. Jänicke, F., Schmitt, M., Fache, L. et al. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 1993, 24: 195-208.
92. Holst-Hansen, C., Johannessen, B., Høyer-Hansen, G., Rømer, J., Ellis, V., Brünner, N. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis 1996, 14: 297-307.
93. Liu, G.M., Shuman, M.A., Cohen, R.L. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int J Cancer 1995, 60: 501-6.
94. Tsuchiya, H., Katsuo, S., Matsuda, E. et al. The antibody to plasminogen activator inhibitor-1 suppresses pulmonary metastases of human fibrosarcoma in athymic mice. Gen Diagn Pathol 1995, 141: 41-8.
95. Soff, G.A., Sanderowitz, J., Gately, S, et al. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest 1995, 96: 2593-600.
96. Ciemiewski, C.S., Babinska, A., Swiatkowska, M., Wilczynska, M., Okruszek, A., Stec, W.J. Inhibition by modified oligodeoxynucleotides of the expression of type-1 plasminogen activator Inhibitor in human endothelial cells. Eur J Biochem 1995, 227: 494-9.
97. Sawa, H., Sobel, B.E., Fujii, S. Inhibition of type-1 plasminogen activator inhibitor production by antisense oligonucleotides in human vascular endothelial and smooth muscle cells. J Biol Chem 1994, 269: 14149-52.
98. Kerins, D.M., Hao, Q., Vaughan, D.E. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 1995, 96: 2515-20.
99. Vaughan, D.E., Lazos, S.A., Tong, K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995, 95: 995-1001.
100. Wright, R.A., Flapan A.D., Alberti, K.G.M.M., Ludlam, C.A., Fox, K.A.A. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol 1994, 24: 67-73.
101. Hamdan, A.D., Quist, W.C., Gagne, J.B., Feener, E.P. Angiotensin-converting enzyme inhibition suppresses plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta. Circulation 1996, 93: 1073-8.
102. Abrahamsson, T., Bjorquist, P., Deinum, J. et al. An antibody fragment against PAI-1 inhibits PAI-1 activity and stimulates fibrinolysis in vitro and in vivo. Fibrinolysis 1994, 8 (Suppl. 2): 55-6.
103. Abrahamsson, T., Nerme, V., Stromqvist, M. et al. Anti-thrombotic effect of a PAI-1 inhibitor in rats given endotoxin.Thromb Haemost 1996, 75: 118-26.
104. Levi, M., Biemond, B.J., van Zonneveld, A.J., ten Cate, J.W., Pannekoek, H. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992, 85: 305-12.
105. Biemond, B.J., Levi, M., Coronel, R., Janse, M.J., ten Cate, J.W., Pannekoek, H. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Circulation 1995, 91: 1175-81.
106. 14 region of the putative reactive bond loop of the inhibitor. J Biol Chem 1992, 267: 1976-82.
107. 1-antitrypsin by a peptide sequentially similar to β-strand s4A. Eur J Biochem 1990, 194: 51-6.
108. Eitzman, D.T., Fay, W.P., Lawrence, D.A. et al. Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro. J Clin Invest 1995, 95: 2416-20.
109. Bryans, J., Charlton, P., Chicarelli-Robinson, I. et al. Inhibition of plasminogen activator inhibitor-1 activity by two diketopiperazines, XR330 and XR334 produced by Streptomyces sp. J Antibiot 1996, 49: 1014-21,
110. Charlton, P.A., Faint, R.W., Bent, F. et al. Evaluation of a low molecular weight modulator of human plasminogen activator inhibitor-1 activity. Thromb Haemost 1996, 75: 808-15.
111. Faint, R.W., Bent, F.M., Barnes, C.S. et al. Plasminogen activator inhibitor-1: Characterization of a low molecular weight inhibitor. Blood Coagul Fibrinolysis 1996, 7: 410-11.
112. Barnes, C.S., Faint, R.W., Dwyer, M.C. et al. Effects of XR5118 on PAI-1 and tPA activity and arterial thrombus formation in the anaesthetized rat. Br J Pharmacol 1996, 118: 97P.
113. Friederichs, P.H., Biemond, B.J., Charlton, P. et al. Reduction in thrombus growth and promotion of fibrinolysis by a low molecular weight inhibitor of PAI-1 in a rabbit thrombus model. Fibrinolysis 1996, 10 (Suppl. 3): 83.